8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 23, 2026·SEC
Material company update
Mar 30, 2026·SEC
Sight Sciences, Inc.(SGHT)Earnings, Financials & Key Ratios
SGHT•NASDAQ
$5.35
Price updated Jul 7, 2026
AboutSight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.Show more
- Revenue$77M-3.1%
- EBITDA-$37M+26.5%
- Net Income-$38M+25.4%
- EPS (Diluted)-0.74+28.2%
- Gross Margin86.17%+0.8%
- EBITDA Margin-47.32%+24.1%
- Operating Margin-47.95%+24.2%
- Net Margin-49.67%+23.0%
- ROE-50.74%-2.3%
SGHT Price & Volume
Sight Sciences, Inc. (SGHT) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Burn Challenges Revenue Growth Trajectory
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Medicare reimbursement policy volatility
Key Thesis Takeaways
- Sight Sciences faces a challenging outlook characterized by volatile revenue growth, which fluctuated between -9.1% and 12.5% over the last ten quarters, and a persistent inability to achieve operating leverage.
- While the company maintains impressive gross margins of approximately 86%, the high SG&A intensity—frequently exceeding $20 million per quarter—continues to drive significant net losses and equity erosion.
- Investors should monitor the company's ability to navigate Medicare reimbursement policy volatility, as current cash burn rates and a shrinking asset base, down from $166.7 million in 2023Q4 to $109.7 million in 2026Q1, suggest a precarious path toward long-term commercial viability.
Verdict Logic
the company's inability to generate positive free cash flow, coupled with a 2026Q1 net loss of $13.0 million and a shrinking cash position of $85.0 million, suggests significant execution risk in the current reimbursement environment.
SGHT Growth Metrics
Sight Sciences, Inc. (SGHT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years22.86%
3 Years2.74%
TTM1.85%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM24.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM27.71%
Return on Capital
10 Years-85.68%
5 Years-33.64%
3 Years-33.55%
Last Year-32.03%
SGHT Recent Earnings
Sight Sciences, Inc. (SGHT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.16+15.8%
$0.19
Rev
$20M+6.7%
$18M
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.08+46.7%
$0.15
Rev
$20M+0.2%
$20M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.16+38.5%
$0.26
Rev
$20M-2.2%
$20M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.23+8.0%
$0.25
Rev
$20M+10.3%
$18M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.16vs $0.19+15.8% | $20Mvs $18M+6.7% |
| Q2 2026 | Mar 4, 2026 | $0.08vs $0.15+46.7% | $20Mvs $20M+0.2% |
| Q4 2025 | Nov 6, 2025 | $0.16vs $0.26+38.5% | $20Mvs $20M-2.2% |
| Q3 2025 | Aug 7, 2025 | $0.23vs $0.25+8.0% | $20Mvs $18M+10.3% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Sight Sciences, Inc. (SGHT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.35 | $291.09M | -7.23 | -3.13% | -49.67% | -50.74% | — | |
| $150.65 | $8.82B | -45.93 | 32.33% | -34.34% | -26.46% | — | |
| $32.80 | $1.66B | -136.67 | 14.88% | -0.83% | -0.95% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $179.95 | $9.42B | -64.27 | -27.1% | 4.9% | 9.08% | — |
Compare SGHT vs Peers
Sight Sciences, Inc. (SGHT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SGHT SEC Filings & Documents
Sight Sciences, Inc. (SGHT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SGHT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SGHT Frequently Asked Questions
Sight Sciences, Inc. (SGHT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Sight Sciences, Inc.'s revenue?
Sight Sciences, Inc. (SGHT) reported $79.6M in revenue for fiscal year 2025. This represents a 956% increase from $7.5M in 2018.
How fast is Sight Sciences, Inc. growing?
Sight Sciences, Inc. (SGHT) saw revenue decline by 3.1% over the past year.
Is SGHT profitable?
Sight Sciences, Inc. (SGHT) reported a net loss of $37.3M for fiscal year 2025.
Dividend & Returns
What is SGHT's return on equity?
Sight Sciences, Inc. (SGHT) has a return on equity (ROE) of -50.7%. Negative ROE indicates the company is unprofitable.
What is Sight Sciences, Inc.'s free cash flow?
Sight Sciences, Inc. (SGHT) had negative free cash flow of $25.4M in fiscal year 2025, likely due to heavy capital investments.